Maureen Ann McGargill

Maureen Ann McGargill

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maureen Ann McGargill has a total of 265 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discovery Stack Pilot demonstrates the feasibility and outcomes of a scientist-designed peer-review model that separates quality and impact

    by Maureen A. McGargill, Beiyun C. Liu, Michael S. Kuhns, Daniel Mucida, Isabella Rauch, Lauren B. Rodda, Meghan A. Koch, Hugo Gonzalez Velozo, Ken Cadwell, Tanya S. Freedman, et al.

    Peer review serves as the cornerstone of scientific quality control. Yet, the current journal-centric system is hindered by long timelines, high publication costs, inconsistent review quality, systemic biases, and editorial gatekeeping. Notably, the system relies on misaligned measures of impact that are tethered to journal branding and conflate scientific rigor ( Quality ) with perceived significance ( Impact ). Here, we report findings from the Discovery Stack Pilot Study, which tested a scientist-designed, journal-independent peer review model. The Discovery Stack model integrates in-line reviewer comments to promote constructive feedback and separately evaluates scientific Quality and Impact using defined criteria. To examine feasibility and effectiveness, manuscripts were reviewed in parallel with traditional journal review. A total of 162 reviews were completed, and survey data from 86 participants were analyzed. The results showed that reviewers effectively evaluated Quality and Impact as separate dimensions, with Quality scores being more consistent across reviewers than Impact scores. Participants strongly supported the core elements of the Discovery Stack model and expressed enthusiasm for its broader adoption to enhance transparency, efficiency, and value in peer review. Future studies will explore integrating this model into a digital platform for reviewing and curating scientific discoveries to improve the production and dissemination of high-quality research.

  • Open Access

    Discovery Stack Pilot: Feasibility and Outcomes of a Scientist-Designed Peer Review Model Separating Quality and Impact

    by Maureen A. McGargill, Beiyun C. Liu, Michael S. Kuhns, Daniel Mucida, Isabella Rauch, Lauren B. Rodda, Meghan A. Koch, Hugo Gonzalez, Ken Cadwell, Tanya S. Freedman, et al.

    Peer review serves as the cornerstone of scientific quality control. Yet, the current journal-centric system is hindered by long timelines, high publication costs, inconsistent review quality, systemic biases, and editorial gatekeeping. Notably, the system is built around misaligned measures of impact that are tethered to journal branding and conflate scientific rigor ( Quality ) with perceived significance ( Impact ). Here, we report findings from the Discovery Stack Pilot Study, which tested a scientist-designed, journal-independent peer review model. The Discovery Stack model integrates in-line reviewer comments to promote constructive, improvement-focused feedback and generates separate, multimodal assessments of scientific Quality and Impact . To examine its feasibility and effectiveness, manuscripts enrolled in the pilot were reviewed in parallel with traditional journal review. A total of 162 reviews were completed, and survey data from 86 participants were analyzed to evaluate the experience of both authors and reviewers. The results showed that reviewers effectively evaluated Quality and Impact as separate dimensions, with Quality scores being more consistent across reviewers than Impact scores. Importantly, participants strongly supported the core elements of the Discovery Stack model and expressed enthusiasm for its broader adoption to enhance transparency, efficiency, and value in peer review. Future studies will explore integrating this model into a digital platform for reviewing and curating scientific discoveries to improve the production and dissemination of high-quality research.

  • Open Access

    Altered germinal center responses in mice vaccinated with highly pathogenic avian influenza A(H5N1) virus

    by Patrick Seiler, Bryan S. Kaplan, David C. Brice, Susu Duan, Lei Li, Maureen A. McGargill, Natalie Lee, Chun-Yang Lin, Rachael Keating, Elena A. Govorkova, et al.

  • DRAK2 regulates myosin light chain phosphorylation in T cells

    by Benjamin A. Wilander, Tarsha L. Harris, Alexandra H. Mandarano, Cliff S. Guy, Mollie S. Prater, Shondra M. Pruett-Miller, Stacey K. Ogden, Maureen A. McGargill

    Death-associated protein kinase-related apoptosis-inducing kinase-2 (DRAK2; also known as STK17B) is a serine/threonine kinase expressed in T cells. Drak2-deficient (Drak2−/−) mice respond effectively to tumors and pathogens while displaying resistance to T cell-mediated autoimmune disease. However, the molecular mechanisms by which DRAK2 impacts T cell function remain unclear. Gaining further insight into the function of DRAK2 in T cells will shed light on differentially regulated pathways in autoreactive and pathogen-specific T cells, which is crucial for improving autoimmune therapies. Here, we demonstrate that DRAK2 contributes to activation of myosin light chain (MLC2, encoded by Myl2) in both murine and human T cells. In the absence of Drak2, the amount of polymerized actin was decreased, suggesting that DRAK2 modulates actomyosin dynamics. We further show that myosin-dependent T cell functions, such as migration, T cell receptor microcluster accumulation, and conjugation to antigen presenting cells are decreased in the absence of Drak2. These findings reveal that DRAK2 plays an important role in regulating MLC activation within T cells.


  • Diet switch pre-vaccination improves immune response and metabolic status in formerly obese mice

    by Rebekah Honce, Ana Vazquez-Pagan, Brandi Livingston, Alexandra H. Mandarano, Benjamin A. Wilander, Sean Cherry, Virginia Hargest, Bridgett Sharp, Pamela H. Brigleb, Ericka Kirkpatrick Roubidoux, et al.

    Metabolic disease is epidemiologically linked to severe complications upon influenza virus infection, thus vaccination is a priority in this high-risk population. Yet, vaccine responses are less effective in these same hosts. Here we examined how the timing of diet switching from a high-fat diet to a control diet affected influenza vaccine efficacy in diet-induced obese mice. Our results demonstrate that the systemic meta-inflammation generated by high-fat diet exposure limited T cell maturation to the memory compartment at the time of vaccination, impacting the recall of effector memory T cells upon viral challenge. This was not improved with a diet switch post-vaccination. However, the metabolic dysfunction of T cells was reversed if weight loss occurred 4 weeks before vaccination, restoring a functional recall response. This corresponded with changes in the systemic obesity-related biomarkers leptin and adiponectin, highlighting the systemic and specific effects of diet on influenza vaccine immunogenicity.


  • Open Access

    Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2

    by Tomer Hertz, Shlomia Levy, Daniel Ostrovsky, Hanna Oppenheimer, Shosh Zismanov, Alona Kuzmina, Lilach M. Friedman, Sanja Trifkovic, David Brice, Lin Chun-Yang, et al.

    Vaccination, especially with multiple doses, provides substantial population-level protection against COVID-19, but emerging variants of concern (VOC) and waning immunity represent significant risks at the individual level. Here we identify correlates of protection (COP) in a multicenter prospective study following 607 healthy individuals who received three doses of the Pfizer-BNT162b2 vaccine approximately six months prior to enrollment. We compared 242 individuals who received a fourth dose to 365 who did not. Within 90 days of enrollment, 239 individuals contracted COVID-19, 45% of the 3-dose group and 30% of the four-dose group. The fourth dose elicited a significant rise in antibody binding and neutralizing titers against multiple VOCs reducing the risk of symptomatic infection by 37% [95%CI, 15%-54%]. However, a group of individuals, characterized by low baseline titers of binding antibodies, remained susceptible to infection despite significantly increased neutralizing antibody titers upon boosting. A combination of reduced IgG levels to RBD mutants and reduced VOC-recognizing IgA antibodies represented the strongest COP in both the 3-dose group (HR = 6.34, p = 0.008) and four-dose group (HR = 8.14, p = 0.018). We validated our findings in an independent second cohort. In summary combination IgA and IgG baseline binding antibody levels may identify individuals most at risk from future infections.


  • Open Access

    DRAK2 contributes to type 1 diabetes by negatively regulating IL-2 sensitivity to alter regulatory T cell development

    by Alexandra H. Mandarano, Tarsha L. Harris, Blaine M. Creasy, Marie Wehenkel, Marygrace Duggar, Benjamin A. Wilander, Ashutosh Mishra, Jeremy Chase Crawford, Sarah A. Mullen, Katherine M. Williams, et al.


  • Open Access

    FLU‐LISA (fluorescence‐linked immunosorbent assay): high‐throughput antibody profiling using antigen microarrays

    by Shlomia Levy, Marwa Abd Alhadi, Asaf Azulay, Amit Kahana, Nir Bujanover, Roi Gazit, Maureen A McGargill, Lilach M Friedman, Tomer Hertz

    Vaccination and natural infection both elicit potent humoral responses that provide protection from subsequent infections. The immune history of an individual following such exposures is in part encoded by antibodies. While there are multiple immunoassays for measuring antibody responses, the majority of these methods measure responses to a single antigen. A commonly used method for measuring antibody responses is ELISA—a semiquantitative assay that is simple to perform in research and clinical settings. Here, we present FLU‐LISA (fluorescence‐linked immunosorbent assay)—a novel antigen microarray‐based assay for rapid high‐throughput antibody profiling. The assay can be used for profiling immunoglobulin (Ig) G, IgA and IgM responses to multiple antigens simultaneously, requiring minimal amounts of sample and antigens. Using several influenza and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antigen microarrays, we demonstrated the specificity and sensitivity of our novel assay and compared it with the traditional ELISA, using samples from mice, chickens and humans. We also showed that our assay can be readily used with dried blood spots, which can be collected from humans and wild birds. FLU‐LISA can be readily used to profile hundreds of samples against dozens of antigens in a single day, and therefore offers an attractive alternative to the traditional ELISA.


  • Open Access

    Correlates of protection for booster doses of the BNT162b2 vaccine

    by Tomer Hertz, Shlomia Levy, Daniel Ostrovsky, Hannah Oppenheimer, Shosh Zismanov, Alona Kuzmina, Lilach Friedman, Sanja Trifkovic, David Brice, Chun-Yang Lin, et al.

    Variants of concern (VOC) of SARS-CoV2 and waning immunity pose a serious global problem. Overall, vaccination and prior infection provide significant protection, but some individuals remain susceptible to infection and severe disease. Rigorously identifying correlates of protection (COP) is necessary to identify these susceptible populations. We conducted a multicenter prospective study assessing the association between serological profiles and the risk for SARS-CoV-2 infection, comparing those vaccinated with three to four doses of Pfizer BNT162b2 vaccine. We identified several IgG and IgA binding markers that were COPs. The strongest COP was reduced IgG levels to RBD mutants and IgA levels to VOCs (three-dose-group HR=6.34, p=0.008; four-dose-group HR=8.14, p=0.018). Most importantly, we identified a subset of vaccinated individuals with low antibody levels that generated a significant boost in neutralizing antibody titers after a fourth dose, but were still at significantly increased susceptibility to infection.

  • SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells

    by Anastasia A. Minervina, Mikhail V. Pogorelyy, Allison M. Kirk, Jeremy Chase Crawford, E. Kaitlynn Allen, Ching-Heng Chou, Robert C. Mettelman, Kim J. Allison, Chun-Yang Lin, David C. Brice, et al.

    Although mRNA vaccine efficacy against severe coronavirus disease 2019 remains high, variant emergence has prompted booster immunizations. However, the effects of repeated exposures to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens on memory T cells are poorly understood. Here, we utilize major histocompatibility complex multimers with single-cell RNA sequencing to profile SARS-CoV-2-responsive T cells ex vivo from humans with one, two or three antigen exposures, including vaccination, primary infection and breakthrough infection. Exposure order determined the distribution between spike-specific and non-spike-specific responses, with vaccination after infection leading to expansion of spike-specific T cells and differentiation to CCR7−CD45RA+ effectors. In contrast, individuals after breakthrough infection mount vigorous non-spike-specific responses. Analysis of over 4,000 epitope-specific T cell antigen receptor (TCR) sequences demonstrates that all exposures elicit diverse repertoires characterized by shared TCR motifs, confirmed by monoclonal TCR characterization, with no evidence for repertoire narrowing from repeated exposure. Our findings suggest that breakthrough infections diversify the T cell memory repertoire and current vaccination protocols continue to expand and differentiate spike-specific memory.